Ocugen, Inc.
OCGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001372299
In the last 90 days, Ocugen, Inc. insiders filed 0 open-market purchases and 1 sale; 147 institutions reported holding it in 13F filings for Q2 2026, worth $222.1M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Ocugen, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 128 | 1 | 114 | −13 |
| Shares | 82.3M | 16.5K | 90.0M | +7.75M (+9.4%) |
| Value | $146.5M | $29.4K | $117.0M | −$29.4M (−20.1%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Ocugen, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 1,422,856 | $1.85M | 0.00% |
| Two Sigma Advisers, LP | 43,200 | $56.2K | 0.00% |
| Perennial Investment Advisors, LLC | 15,000 | $19.5K | 0.01% |
| Creative Planning | 14,418 | $18.7K | 0.00% |
| Verition Fund Management LLC | 14,000 | $18.2K | 0.00% |
| Tudor Investment Corp Et Al | 13,962 | $18.0K | 0.00% |
| Pictet Asset Management SA | 12,280 | $16.0K | 0.00% |
| Lanham O'Dell & Company, Inc. | 10,050 | $13.1K | 0.03% |
| Lazard Asset Management LLC | 8,971 | $11.0K | 0.00% |
| Bank of Montreal | 5,953 | $7.80K | 0.00% |
| The PNC Financial Services Group, Inc. | 775 | $1.01K | 0.00% |
| Global Wealth Strategies & Associates | 300 | $390 | 0.00% |
| Belpointe Asset Management LLC | 299 | $389 | 0.00% |
| Advisory Services Network, LLC | 270 | $351 | 0.00% |
| NewSquare Capital LLC | 50 | $65 | 0.00% |
| Parkside Financial Bank & Trust | 49 | $64 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 9 | $11 | 0.00% |
Sold out (30)
Institutions that held Ocugen, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (1)
Institutions that held Ocugen, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Portfolios Advisors | 16,500 | $29.4K |